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The wearable cardioverter-defibrillator has been available for over a decade and now is frequently prescribed for patients deemed at high
arrhythmic risk in whom the underlying pathology is potentially reversible or who are awaiting an implantable cardioverter-defibrillator.
The use of the wearable cardioverter-defibrillator is included in the new 2015 ESC guidelines for the management of ventricular arrhythmias
and prevention of sudden cardiac death. The present review provides insight into the current technology and an overview of this approach.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Wearable cardioverter-defibrillator † Sudden cardiac death † Ventricular arrhythmias † External defibrillation †
Life vest
Introduction
The implantable cardioverter-defibrillator (ICD) is central in the
prevention of sudden cardiac death (SCD). Current guidelines rec-
ommend ICD implantation for secondary and primary prevention in
patients with an established high risk of SCD.1,2 However, in certain
patients, the risk of SCD may be increased only temporarily or
cannot be determined immediately, because risk stratification takes
time. After preclinical testing and the first clinical trial, the wearable
cardioverter-defibrillator (WCD) was approved for clinical practice
in 2001 to bridge a period of actual or presumed high risk of SCD.3,4
The number of patients protected by WCD is rapidly growing;
hence, it is difficult to give an official number here. According to
the manufacturer’s database, the 100 000 patient mark had been
crossed in 2013 (Sven Reek had communication with Mr. Horst
Esser from ZOLL).
The purpose of this manuscript is to describe the technical as-
pects of the WCD, to discuss the indications, to report the clinical
experience, and to provide available results of this approach.
Technology overview
Currently, only one WCD system (LifeVestw, ZOLL, Pittsburgh, PA,
USA) is available. The WCD is a system that consists of a harness-
style vest that contains non-adhesive dry tantalum oxide capacitive
sensing electrodes and self-gelling defibrillator electrodes. This light-
weight vest (0.8 kg) is designed to be worn continuously under nor-
mal clothing and is available in different sizes. A monitor is worn
around the waist (or shoulder harness) and contains the sensing
circuits along with batteries and capacitors (Figure 1). The device
has a system of audible and vibratory alerts to warn a patient of
an imminent shock. The patient can abort the shock by pressing but-
tons on the monitor. Data from the monitor can be transmitted to
the patient’s physician for offline analysis.
Arrhythmia detection
The harness contains four sensing electrodes (anterior/posterior/
right/left) that produce a two-lead filtered ECG. The arrhythmia
detection algorithm combines heart rate data with morphology
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analysis. If morphology analysis is not available due to technical is-
sues (e.g. noise interference), the algorithm reverts to just heart
rate detection using rate, stability, and onset criteria. The heart
rate is judged by the algorithm from multiple sources (on each
channel, using fast Fourier transform). The algorithm compares
the analysed heart rates from the two leads. If these rates differ sig-
nificantly, less weight is applied to heart rate in arrhythmia discrim-
ination. Once heart rate is established, the algorithm triages the
rhythm into pre-programmable thresholds for ventricular tachycar-
dia (VT) or ventricular fibrillation (VF). Once one of these thresh-
olds is exceeded, the algorithm moves on to morphology analysis
using the two leads in orthogonal axes and compares the real-time
tracing to the templates collected in normal rhythm. A sensing cir-
cuit allows detection of electrode fall-off, which will result in system
reverting to single lead detection.
The detection algorithm uses a ‘confidence level’ weighted score
based upon heart rate, morphology, use of the patient response
button, and signal quality.5 Each of these factors can contribute
negatively or positively to the overall result. The design goal was
to only shock if the VT was at least 30 s long. Thus, the alarms
were designed to last a minimum of 30 s. The algorithm continuous-
ly evaluates the ECG during the alarms. Basically, the algorithm
reviews a moving window of parameters. If the rate drops below
the detection threshold for a brief period (a few seconds), then
detection will be delayed (extended to see whether the lower
rate persists or whether it was just an aberration), and if it persists,
the detection will stop. As a result, the median time from arrhythmia
onset to shock delivery is 45 s (Figure 2).
Patient interaction
The system evaluates the patient’s consciousness by assessing
response to the escalating alerts. Response buttons are located
on either side of the monitor (Figure 3). The patient needs to press
both buttons simultaneously and continue to hold them for therapy
to be withheld. If the patient does not press or release them, the es-
calating warning system continues until finally an audible message for
bystanders to stand clear is emitted. This unique patient interaction
feature contributes to optimization of the sensitivity and specificity
of the algorithm.6
Therapy
The device will deliver up to five shocks within a single arrhythmia
episode. After five shocks, the device reverts to sensing and will
repeat the cycle until either the rate drops below that required
for VT/VF detection or the battery has depleted. The time to deliver
therapy can be programmed in the different zones (60–180 s for VT
and 25–40 s for VF). Appropriate programming of VT and VF zones
is crucial to avoid inappropriate shock delivery. Programming VT
rate to .180 bpm and the VF zone to .220 bpm substantially
reduces the incidence of noise alarms that may lead to frequent
response button use.
After a failed first shock, the second therapy is delivered 60 s
after the first detection of VF or 2 min after VT detection. This could
be longer depending upon the programmed delay.
Shock therapy is a biphasic truncated exponential waveform and
can be programmed from 75 to 150 J. Patients are usually given two
rechargeable lithium ion batteries that are charged via a base station.
While one is in the monitor, the other is usually on charge. Each
battery will run the monitor for at least 2 days. If the battery indi-
cates that it needs recharging, it will usually have sufficient charge
to deliver around ten 150 J shocks.
Patient training and follow-up
Appropriate patient training for correct WCD use is provided by
the technical personnel of the manufacturer and includes instruction
on battery charging and data transfer to the network server. After
the initial training, which may last an hour or more, the technical
personnel contact the patient within the next few days to avoid
potential problems of device use. Patients or their relatives can
contact the 24/7 hotline for questions or in case of problems.
Data from any episode can be relayed to a secure server in a
similar manner to conventional remote follow-up via the cellular
mobile phone network. The monitor attempts to connect once a
day if in the proximity of the base station. This allows for an individu-
ally tailored set of alerts to be programmed that can monitor
arrhythmias, patient use (i.e. hours/day worn), and patient-triggered
recordings. Since all VT/VF events are stored in the LifeVestw
Network server (https://lifevestnetwork.zoll.com), the physician is
automatically notified of an arrhythmia event or shock delivery.
This system also provides information on wearing time, ECG quality,
and occurrence of false alarms due to noise.
A weekly data transmission is requested, and monthly office visits
are recommended. After a shock delivery, the garment needs to be
replaced immediately.
Clinical experience with wearable
cardioverter-defibrillator
The WCD was first described in 1998.3 Since then, several case ser-
ies and registries on the use of WCD have been published (Table 1).
It has been shown that WCD is safe and effective in terminating
VT/VF in high-risk patients with a temporary risk of SCD or when
the risk is unknown or cannot be determined yet. So far, no
Figure 1 Patient wearing device.
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Figure 2 (A) Flow chart indicating sequence of patient and bystander alerts after treatment sequence initiated. The patient prompt is: ‘Press the
response button to delay treatment, electrical shock possible’. The bystander alert is: ‘Do not touch patient’. (B) WCD shock delivery in a
68-year-old male patient 2.5 months after acute myocardial infarction; initial LVEF 22%; a–c: ECG recording (SS lead) of 16 s prior to onset of
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randomized, controlled outcome studies for specific patient popu-
lations and indications are available. Nonetheless, several inter-
national societies have included the WCD in their consensus
statements and guidelines (Table 2).
The European experience
The WCD was first used in 1998 at the University Hospital
Magdeburg, Germany, in 10 patients with induced VT/VF in the cath-
eterization laboratory.3 At this time, the WCD delivered monopha-
sic shocks. A new WCD using impedance-compensatory biphasic
truncated exponential waveforms was later tested in 12 patients
with 22 induced VT/VF episodes with 100% first shock termination.7
The first prospective clinical efficacy trial of the WCD (WEARIT/
BIROAD study) was published in 2004.4 This was a combined US/
Germany study, performed in 289 patients with either severe heart
failure, early after myocardial infarction (MI), or after coronary
artery bypass surgery (CABG) with reduced left ventricular ejection
fraction (LVEF). The trial was terminated after six out of eight
successful defibrillations of VT/VF episodes. Inappropriate shocks
occurred in 0.7% per month of use.
Despite the promising experience of the WEARIT/BIROAD
study, only few university hospitals prescribed WCDs in Germany
and a few other European hospitals also prescribed WCDs. In
2010, Klein et al. reported the first German experience with
WCD in 354 patients from 43 different hospitals.8 The mean age
was 57 years, with 10% of patients being younger than 40 years
and 29% older than 70 years. The mean wearing period of WCD
was 3.5 months, with a mean wearing time/day of 21.3 h. Arrhythmia
events (VT/VF) occurred in 27 patients (7.6%). Shock delivery
was necessary in 11 patients with 21 VT/VF episodes. Twenty of
21 VT/VF events were successfully terminated by the first shock
with programmed shock energy of 150 J. One patient needed
two shocks to terminate VF. Additional VT events were either
non-sustained (lasting 15-30 sec) or sustained (lasting .30 sec),
but self-terminating arrhythmia or use of the response buttons
withholds shock delivery in conscious patients with sustained VT. In-
appropriate detection of rapid supra-VT was noted in eight patients,
none of them leading to shock delivery because of response button
use (inappropriate shocks in ,0.1%/month). Asystole occurred in
two patients with LVEF , 15% and severe heart failure and both
of them died.
Within the last 5 years, WCDs are being increasingly used in
Europe. According to the data from the manufacturer (personal
communication), 20 000 WCDs have been prescribed in Europe,
the vast majority in Germany, followed by the Netherlands, France,
Italy, Switzerland, and Austria. Non-ischaemic cardiomyopathy
(NICM) including acute myocarditis with recent onset of severe
heart failure is the most frequent reason for WCD prescription,
followed by early post-MI, with or without revascularization proce-
dures, patients after CABG or other heart surgery procedures with
severely reduced LVEF, syncope of unknown origin with structural
heart disease, risk stratification period for suspected inherited
arrhythmia syndromes, intermittent ICD explant for infection,
delayed ICD implantation because of serious co-morbidities, and
finally rare indications such as waiting for heart transplant or use
of left ventricular assist device (LVAD) instead of ICD implantation
(Figure 4). This is slightly different from the prescription practice in
the USA where the majority of WCD prescriptions are for the early
phase after MI.9
A recent analysis showed that 94 of 6043 (1.6%) patients experi-
enced appropriately delivered shocks for rapid VT (.220 bpm) or
VF which may have been life-saving (Figure 2B).23 All VT/VF episodes
were appropriately detected and treated. Post-treatment survival
was 93%. The incidence of inappropriately delivered shocks was
0.4% of all patients provided with the new WCD system. Inappro-
priate shocks mainly occurred because of noise, rapid regular
supra-VT, or atrial fibrillation.
Currently, 5% of patients for whom the WCD is prescribed are
ultimately considered unsuitable for appropriate and safe handling
of the system.24 Despite the increase of WCD prescriptions, death




The WCD was approved by the US Food and Drug Administration
in 2001 and is covered by most health plans.25 Indications for use are
listed in Table 3 and include primary and secondary prevention of
SCD in patients with ischaemic and non-ischaemic heart disease
in a variety of situations especially during the mandatory waiting per-
iods after MI and the diagnosis of cardiomyopathy when medical
therapy is being optimized to improve LVEF.1,25
In 2010, Chung et al. reported the aggregate national experience
using the device in 3569 patients with a wide spectrum of indications
including LVEF ≤ 35% after recent MI, post-CABG, VT/VF before
ICD implantation following ICD explantation, and a presumed gen-
etic predisposition to SCD (Table 1).9 The patients’ mean age was
59.3+ 14.7 years, and the WCD was worn for 52.6+ 69.9 days.
Eighty sustained VT/VF events occurred in 59 patients (1.7%), and
first shock was successful in all 76 episodes of unconscious VT/VF
Figure 3 Wearable defibrillator system showing device, vest,
and remote monitor. Arrow (upper left) indicates patient re-
sponse button with second button on opposite side of device.
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and 79/80 (99%) of all VT/VF episodes. Eight patients died after
successful conversion of unconscious VT/VF (89.5% survival of the
events). Asystole occurred in 23 patients (17 died), pulseless elec-
trical activity in 2, and respiratory arrest in 1 (all 3 died), representing
24.5% of sudden cardiac arrests (SCAs). This demonstrates that
SCD is not necessarily due to VT/VF and that not all patients with
SCA can be resuscitated by defibrillation. The authors concluded
that wearing compliance was satisfactory with 90% wear time in
.50% of patients and that SCD mortality during use was low.
The benefit of WCD use was described in patients with LVEF ≤
35% after CABG or PCI (Table 1).12 Following revascularization pro-
cedures, early mortality risk was lower (HR, 0.54; 95% CI, 0.43–0.68;
P , 0.0001) among 809 patients discharged with WCD compared
with 4149 discharged without WCD. Ninety-day mortality post-
CABG was 7% without vs. 3% (P ¼ 0.03) with WCD. Mortality post-
PCI was 10% without vs. 2% (P , 0.0001) with WCD use. The use
of WCD was also associated with a 39% (HR, 0.61; 95% CI, 0.49–
0.78; P , 0.0001) adjusted lower risk of long-term mortality at 3.2
years for both CABG (HR, 0.62; 95% CI, 0.38–0.997; P , 0.048)
and PCI (HR, 0.43; 95% CI, 0.29–0.64; P , 0.0001) patients. It is to
emphasize that this study was not a randomized prospective study,
and therefore, these data have to be interpreted with caution.
Device guidelines and insurance coverage in the USA require
waiting periods of either 40 days or 3 months before implanting
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Summary of WCD trials and registries
Study No.
of pts
Inclusion criteria Design Main findings
Auricchio et al.3 10 Pts undergoing EPS for VT/VF Observational, clinical
testing
10/10 episodes of induced VT/VF were successfully
terminated with first 230 J monophasic shock in
10 Pts
Reek et al.7 12 Pts undergoing EPS for VT/VF Observational, clinical
testing
22/22 episodes of induced VT/VF were successfully
terminated with first 70 J or 100 J biphasic shock in
12 Pts
Feldman et al.4 289 WEARIT: heart failure NYHA III/IV
BIROAD: high risk after MI/CABG
Prospective cohort study 6/8 episodes of spontaneous VT/VF were successfully
terminated during mean FU of up to 4 months
Klein et al.8 354 High risk after MI/CABG, Pts awaiting
HTX, ICD explant + delayed
implant, risk stratification
Retrospective, registry data 20/21 VT/VF episodes were successfully terminated by
first shock during a mean wear time of 3 months
Chung et al.9 3569 Various indications according to CMS
coverage
Retrospective, registry data Compliance was high, and SCD mortality was low during
WCD use comparable to that of ICD Pts; 79/80
VT/VF episodes were successfully terminated by first
shock during a mean wear time of 53 days
Rao et al.10 162 CSHD, IAS Prospective observational,
registry data
WCD can be safely used in high-risk adults with CSHD
and IAS; 3 VT/VF episodes were successfully
terminated by the first shock during a mean wear
time of 29 days
Saltzberg et al.11 266 PPCM, NICM Retrospective, registry data No arrhythmic events and low mortality rate in Pts with
PPCM
Zishiri et al.12 809 Pts after CABG/PCI with LVEF ≤ 35% Prospective observational,
registry data
WCD use was associated with lower short- and
long-term mortality than no WCD use in high-risk
Pts after CABG or PCI; 12/18 (1.3% event rate)
VT/VF episodes were successfully terminated
Epstein et al.13 8453 Recent MI with LVEF ≤ 35% Retrospective, registry data 133 Pts (1.6%) received 309 shocks for VT/VF during
40-day and 3-month waiting periods after MI; 91%
were successfully resuscitated
Duncker et al.14 7 PPCM Prospective cohort study Four episodes of VF were successfully terminated by the
first WCD shock in 3/7 Pts during mean wear time of
81 days
Kutyifa et al.15 2000 High-risk ICM, NICM, CSHD/IAS Prospective observational,
registry data
VT/VF event rates of 3% in ICM and CSHD/IA,
respectively, and 1% in NICM during mean wear time
of 3 months; 30/30 episodes of spontaneous VT/VF
successfully terminated by the first shock
Singh et al.16 525 Newly diagnosed ICM and NICM Prospective observational,
registry data
Very low arrhythmic risk in Pts with NICM, 2.2% of ICM
Pts received appropriate shock for VF
WCD, wearable cardioverter-defibrillator; Pts, patients; EPS, electrophysiological study; VT, ventricular tachycardia; VF, ventricular fibrillation; WEARIT, Wearable Cardioverter
Defibrillator Investigational Trial; BIROAD, Bridge to ICD in Patients at Risk of Sudden Arrhythmic Death, NYHA, New York Heart Association functional class, MI, myocardial
infarction, CABG, coronary artery bypass surgery; HTX, heart transplantation; ICD, implantable cardioverter-defibrillator; CMS, Centers for Medicare & Medicaid Services; SCD,
sudden cardiac death; FU, follow-up; CSHD, congenital structural heart disease; IAS, inherent arrhythmia syndromes; PPCM, peripartum cardiomyopathy; NICM, non-ischaemic
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an ICD post-MI depending on whether or not acute revasculariza-
tion was undertaken.1 Epstein et al.13 used the manufacturer’s
database to describe the use of WCD during these mandated
waiting times for patients perceived to be at high risk for SCD
(Table 1). Of 8453 patients, 133 (1.6%) received 309 appropriate
shocks of whom 91% were successfully resuscitated. Of the latter,
3 died within 2 days and 41 died ≥3 days after shock delivery. For
patients who received shock therapy, LVEF was ≤30% in 106, and
the median time from the index MI to WCD therapy was 16 days.
Overall, during the 40-day and 3-month waiting periods post-MI,
WCD successfully treated SCA in 1.4%, and the risk was highest
in the first month of WCD use. The authors concluded that
WCD may benefit individual patients selected for high risk of
SCD early post-MI.
Patient experience and satisfaction
The concept of the WCD requires that the device is worn most of
the time. Therefore, patient compliance is essential and has been a
matter of concern. The use of WCD can be easily monitored online.
Registry data show that patient compliance is high. Chung et al.9
reported that 52% of patients used the WCD . 90 and 71% of
patients .80% per day. In the German case series, daily use was
.90% in 72% of patients.8 Longer periods of use correlate with
higher daily wear times.5,15
So far, there has been no prospective evaluation of patient satis-
faction or psychological impact of WCD use. Klein et al.8 performed
an interview in 60 patients. The vast majority reported that the
device was easy to handle after appropriate training and gave
them a feeling of safety and trust. Reasons for patient complaints
were mostly the weight of the monitor unit and disturbance by noise
alarms causing sleeping disturbances in 25%. These were the main
reasons to stop wearing WCD prematurely in 5–14% of assigned
patients.8,9,26
Table 2 Representation of WCD in guidelines and position papers
2006 ACC/AHA/ESC 2006 Guidelines for management of patients with
ventricular arrhythmias and prevention of sudden cardiac death.17
Quotation of FDA approval of the WCD for cardiac patients with a
transient high risk for VF such as those awaiting cardiac transplantation,
those at very high risk after a recent MI or an invasive cardiac procedure,
or those requiring temporary removal of an infected ICD for antibiotic
therapy.
2006 International Society for Heart and Lung Transplantation guidelines
for the care of cardiac transplant candidates.18
Class I indication for WCD prescription for status 1B patients who are
discharged home given that the wait for transplantation remains
significant.
2009 Transvenous lead extraction: Heart Rhythm Society expert
consensus on facilities, training, indications, and patient
management.19
Recommendation to consider the WCD as an alternative to early ICD
re-implantation after device explant when there is concern of ongoing
infection.
2013 ACCF/AHA guideline for the management of ST-elevation
myocardial infarction.20
Usefulness of a WCD in high-risk patients during the first 4 to 6 weeks after
ST elevation myocardial infarction is under investigation.
2014 EHRA/HRS/APHRS Expert consensus on ventricular arrhythmias.21 Patients with impaired LV function early after MI with or without
revascularization are at increased risk for SCD and may benefit from
WCD until reassessment of LV function.
2014 HRS/ACC/AHA Expert consensus statement on the use of ICD
therapy in patients who are not included or not well represented
in clinical trials.22
The WCD may be an option as a ‘bridge to ICD’ for selected patients at
high risk of sudden cardiac death due to ventricular arrhythmias,
although the data are scant.
2015 ESC guidelines for the management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death.2
In patients with transient impaired LVEF, the WCD may be used until LV
function has recovered sufficiently, following insults such as myocardial
infarction, post-partum cardiomyopathy, myocarditis or interventions
such as revascularization associated with transient LV dysfunction.
Similarly, patients with a history or at risk of life-threatening VAs or who
are scheduled for cardiac transplantation may be temporarily protected
with the WCD.
ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; FDA, Food and Drug Administration; WCD, wearable
cardioverter-defibrillator; VF, ventricular fibrillation; MI, myocardial infarction; ICD, implantable cardioverter-defibrillator; ACCF, American College of Cardiology Foundation;











Figure 4 Distribution of indications for WCD prescription in
Europe between April 2010 and October 2013 in 6043 patients
(modified from Ref. 23).
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When should we use the wearable
cardioverter-defibrillator?
About one-quarter of ICDs may not be indicated and are inappro-
priately implanted; conversely, the same proportion of patients in
whom an ICD is indicated do not receive this therapy.27 The
WCD can be used to determine appropriateness for ICD implant-
ation, specifically a persistent risk for life-threatening arrhythmias
(low LVEF after guideline-directed waiting periods for optimized
medical therapy) or, in case of a reversible cause, to prevent un-
necessary ICD implantation. The 2015 ESC guidelines give a IIb, level
of evidence C indication for WCD in case of ‘adult patients with
poor LV systolic function who are at risk of sudden arrhythmic death
for a limited period but are not candidates for an ICD (e.g. bridge to
transplant, bridge to transvenous implant, peripartum cardiomyop-
athy, active myocarditis, and arrhythmias in the early post-MI
phase)’.2 Potential indications for WCD are listed in Table 3.
Wearable cardioverter-defibrillator use
early after myocardial infarction
Even after immediate revascularization in cases of acute MI with
significantly compromised LVEF, 10–15% of patients will continue
to suffer from severely reduced LVEF. The VALIANT trial showed
that the incidence of SCD was 2.3% within the first month after
MI and decreased significantly within the following months.28 How-
ever, two studies, DINAMIT and IRIS, demonstrated that overall
mortality was not reduced with ICD implantation early after MI
despite significantly reduced SCD events.29,30 For this reason,
guidelines generally do not recommend implanting an ICD within
40 days of an acute MI.1,2
Several studies describe the use of WCD to bridge the 40- or
90-day period after MI with or without revascularization.4,8,9,12,13,15,16
Whether this strategy will improve overall outcome is being evalu-
ated in the ongoing VEST trial.31 Patients with an acute MI and
LVEF ≤ 35% are randomized prospectively to either WCD or con-
ventional medical therapy within the first 90 days after MI.
The REFINE trial showed an 18% increase in LVEF within the first
2 months after acute MI.32 The WEARIT-II Registry showed that
40% of patients with acute MI improved their LVEF beyond the
justifying value for ICD implantation within 3 months.15
The 2013 ACCF/AHA guideline for the management of
ST-elevation MI recommends WCD for up to 3 months in patients
with reduced LVEF in the early phase of acute MI.20 The 2015 ESC
guidelines more critically recommend WCD within 40 days of an
acute MI in selected patients (those with incomplete revasculariza-
tion, pre-existing left ventricular dysfunction, or occurrence of
ventricular arrhythmias after 48 h).2
Wearable cardioverter-defibrillator use
after revascularization procedures
Implantation of ICD after elective revascularization procedures
(CABG or PCI) in patients with reduced LVEF (≤ 35%) is not re-
commended for 3 months as left ventricular function may improve.1
Data from Zishiri et al.12 have demonstrated that patients during this
time period after revascularization procedures experience
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Summary of accepted and potential WCD indications
Clinical situation Period of WCD wearing End of WCD usage
Accepted indicationsa
Acute myocardial infarction with LVEF ≤ 35% 40–90 days LVEF improvement or indicated ICD
implantation
Before/after revascularization procedures (CABG/PCI) with
LVEF ≤ 35%
3–4 months LVEF improvement or indicated ICD
implantation
Recent onset cardiomyopathy NICM or presumed
myocarditis with acute heart failure and/or LVEF ≤ 35%
3–6 months LVEF improvement or indicated ICD
implantation
Intermittent bridging after ICD removal (e.g. infection) 1–2 months Completion of antibiotic therapy and ICD
re-implantation
Delayed but indicated ICD implantation 2–3 months or longer Resolution of cause of delay
Bridge to heart transplantation Variable Until heart transplantation
Potential indications
Period of risk stratification in cases with syncope/cardiac arrest
of unknown origin; cases with suspected inherited arrhythmia
syndromes
Usually 1–3 months Until risk has been defined
Protection in patients with LV assist device Undetermined Until heart transplantation, at the end of a risk
stratification prior or until ICD
implantation
Potentially dangerous ECG changes with drugs (e.g. QT
prolongation)
Variable, depends on continuous drug
administration or elimination
kinetics
Withdrawal of the drug and normalization of
ECG changes
WCD, wearable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter-defibrillator; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; LV, left ventricular.
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significantly less SCD and all-cause mortality when protected by
WCD compared with a similar patient cohort without WCD.
Therefore, high-risk patients after revascularization procedures
can be protected by the WCD until ICD implantation is either
guideline based or may not be indicated.
Wearable cardioverter-defibrillator
use in patients with non-ischaemic
cardiomyopathy and myocarditis
Dilated cardiomyopathy in the absence of coronary artery disease
(NICM) represents a heterogeneous group of diseases including
inflammatory, toxic, metabolic, genetic, or auto-immunological pro-
cesses that most often are discovered in the context of acute heart
failure. Arrhythmic events or aborted SCDs are not rarely first
signs of NICM. Implantable cardioverter-defibrillator implantation
for primary prevention of SCD is currently recommended after
.3 months of optimal medical therapy after the first diagnosis
of heart failure and depressed LV function (LVEF ≤ 35%) with
NICM.1,2
Recent onset cardiomyopathy (ROCM) is not rarely associated
with a recovery of LVEF or reverse remodelling. However, arrhyth-
mic risk and recovery of LVEF may be unpredictable after initial
diagnosis. Several studies describe the use of WCD during the initial
3–4 months after newly diagnosed NICM.4,8,9,15,16 The results
show that the rate of appropriate shocks in patients with NICM is
generally lower than that in ICM. In a very recent study, the event
rate was 0 in 56.7 patient-years of use.16 The authors concluded
that the use of WCD in this population needs to be evaluated in
prospective studies.
Several subgroups of patients with ROCM may have a higher risk
of SCD and were under-represented in these case series. In a cohort
of 181 patients with myocarditis, 13 died suddenly. The risk was
highest in the first 18 months.33 Autopsy data suggest myocarditis
in SCD of young athletes at rates of 9–44%.2,34,35 Severe heart fail-
ure, immunohistological signs of inflammation, and lack of b-blocker
therapy were risk factors for cardiac death and transplantation.33
Bridging the first months of a newly diagnosed myocarditis with
the WCD may therefore be an important step to final decision-
making for either longstanding or unnecessary ICD therapy.
Patients with Takotsubo cardiomyopathy demonstrate a clinical
heterogeneity. Some patients may develop ventricular arrhythmias
especially within the first weeks of diagnosis. The incidence varies
from ,1% to .8%.36– 38 Especially patients who develop QT pro-
longation with Takotsubo cardiomyopathy are at increased arrhyth-
mic risk and can be protected by WCD until LVEF recovery.37,39,40
Deeprasertkul et al.41 describe WCD use in 102 patients with
Takotsubo cardiomyopathy. Two patients received appropriate
shocks during a mean follow-up of 44 days and survived.
Some patients with peripartum cardiomyopathy may present
with severely reduced LVEF and increased risk of SCD.42,43 About
half of these patients will show significant or even full recovery of
LVEF. Effective protection with WCD for 3–6 months has recently
been demonstrated in patients with peripartum cardiomyopathy
and LVEF ≤ 35%. Duncker et al.14 observed four VF events with
successful WCD shocks in 3 out of 7 patients during a median
wear time of 81 days.
Bridge to heart transplantation
Using WCD to bridge the period of risk while awaiting transplant-
ation has been reported.18,44 Opreanu et al. report WCD use in 121
patients awaiting heart transplantation. Patients used the device for
an average of 127 days until ICD implantation or transplantation.
Seven patients received appropriate shocks; all of them survived.
There were two patients with inappropriate shocks for atrial fibril-
lation with rapid response. Two patients with asystole episodes
died. The use of WCD in this population showed high compliance,
efficacy, and a low complication rate.44
Patients with LVADs are at high risk of ventricular tachyarrhyth-
mias. Implantable cardioverter-defibrillator therapy is common, but
goes along with a relatively high complication rate.45 Protecting
those patients with the WCD instead of using an ICD may be a rea-
sonable alternative; however, until now no study data are available.
Temporary protection after implantable
cardioverter-defibrillator explant
When infection of the ICD mandates system removal, antibiotic ther-
apy is often necessary for weeks before re-implantation. During this
period, the WCD is an appropriate approach to prevent long-lasting
and expensive hospital staying until a new device can be implanted.19,46
Other potential applications of the
wearable cardioverter-defibrillator
Patients with advanced renal dysfunction who need haemodialysis
bear a higher risk of SCD, particularly within the first few months
of haemodialysis. Since ICD implantation bears a relatively high
risk of complications, using the WCD for a few months until the
clinical situation is stabilized represents a promising alternative to
ICD therapy.47–49
Many drugs are known to prolong the QT-interval and increase
the risk of life-threatening arrhythmias. Wearing WCD for the
time of necessary drug intake may help to lower the risk of SCD
in selected cases. The use of WCD to bridge curative radiotherapy
for cancer has been described.50 This strategy may be useful in case
the ICD is damaged by radiotherapy or needs to be explanted
because it causes shielding, or in case ICD indication needs to be
re-evaluated based on remission of the cancer.
Costs and cost-effectiveness of the
wearable cardioverter-defibrillator
The WCD is not available for sale by the manufacturer, but is rented
in monthly increments to the patient. The price of the device is
$3300 per month in the USA. In Europe, it is 3000E/month in-
cluding servicing. The WCD has gained full reimbursement approval
in Germany, France, Switzerland, Austria, Luxembourg, USA, and
Japan, whereas in countries like the UK, Netherlands, and Italy, costs
of WCD have to be paid by the hospitals.
Cost-effectiveness of WCD strongly depends on the indication
for use and correct patient selection. Registry data indicate that
the number needed to treat to save one life with WCD varied
between 70 and 110 over a median of 53–57 days.26 A cost-
effectiveness analysis using a Markov model, early after MI, has
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recently been published.51 Patients with an LVEF of ,35%, after MI
or who had undergone coronary revascularization, were studied for
a 3-month period with or without WCD. The model assumed that
56% of the patients would be eligible for an ICD implantation at the
end of the waiting period. The monthly cost of WCD for the model
was $2754, with an SCA rate of 2.25% during the first month and 1%
during the 2 subsequent months. The WCD strategy improved life
expectancy by 0.261 years with an incremental cost-effectiveness
ratio (ICER) of $60 600 per quality-adjusted life year (QALY). The
model was sensitive to the SCA rate, with a reduction of the
ICER to $42 100 per QALY if the rate was 4% during the first month,
and increased to .$100 000 per QALY when the rate in the first
month was ,1.163%. Arrhythmic event rates in all published series
using WCD after MI were above this threshold.4,8,9,13,15,16 The mod-
el was also sensitive to the cost of WCD. If the monthly cost was
reduced to $2000, the ICER improved to $49 100 per QALY. Con-
versely, if the cost was increased to $3500 per month, the ICER be-
came less attractive at $71 900 per QALY.
Another cost-effectiveness analysis of WCD in the setting of ICD
explant for up to 8 weeks due to infection has been recently pub-
lished.52 The ICER of WCD strategy was $26 436 per QALY as
compared to discharge home without WCD. In-hospital monitoring
and discharge to a specialized nursing facility resulted in higher costs
and worse clinical outcome. The analysis was sensitive to WCD
efficacy, SCA event rate, and delay to ICD re-implantation. The
WCD strategy remained cost-effective with the base-case assump-
tions, as long as the delay to re-implantation was at least 2 weeks.
These data suggest that bridging a temporarily increased risk
of SCD using WCD may be cost-effective in selected patient groups.
Cost-effectiveness is mainly determined by the event rate during the
wearing period and the frequency of ICD implantations thereafter.
When WCD was used to bridge a time period for risk stratification
in patients with ICM or NICM, only 40% of patients received
an ICD implantation thereafter.9,15,16 Therefore, unnecessary ICD
implants that had been avoided should be included into cost-
effectiveness analyses. As with all cost-effectiveness analyses using
Markov models, results are speculative. This is particularly true for
the WCD since there are no randomized trials, which makes it
difficult to evaluate the true clinical effectiveness of the therapy.
Limitations and shortcomings
The benefit of the WCD is dependent on patient selection, appro-
priate device use, patient compliance, and appropriate programming
to avoid inappropriate shocks.5 Owing to the lack of randomized
trials, indications for WCD use are based on expert opinion and
clinical judgement. Currently, the vast majority of WCDs have
been prescribed by arrhythmia specialists who are experts in the
field of ICD therapy and prevention of SCD. If the WCD were to
be prescribed by physicians less experienced in the management
of arrhythmias, the benefit may be lower and increased complica-
tions may occur.
Patient compliance is mandatory for appropriate WCD perform-
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Figure 5 WCD decision-making algorithm to optimize ICD therapy. Current indications include patients who meet criteria for ICD implant-
ation when implant is delayed or as an alternative to ICD implantation for certain time periods (red). WCD should also be considered in patients
with severely reduced LVEF who are thought to be at high risk of SCD when the risk is only temporary or cannot be determined yet (turquoise).
WCD, wearable cardioverter-defibrillator; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic
cardiomyopathy; HTX, heart transplantation; VAD, ventricular assist device; IAS, inherent arrhythmia syndromes; MI, acute myocardial infarction;
PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; ROCM, recent onset of cardiomyopathy; CM, cardiomyopathy;











ercio user on 15 D
ecem
ber 2020
necessary. A well-fitting electrode belt is important to ensure
reliable arrhythmia detection. The main reason for inappropriate
detection is noise from the sensing electrodes. Inappropriate shocks
can be avoided by pressing and holding the response buttons. About
5% of all patients who are considered candidates for the WCD will
be unsuitable or unwilling to wear the WCD. In most reports,
between 5 and 14% of patients stopped WCD use prior to the
planned wearing time, mostly because of the monitor weight and
wearing discomfort.8,9,26
The detection algorithm records bradycardia and asystole events,
but does not provide back-up anti-bradycardia or anti-tachycardia
pacing. Registry data reported asystole in 0.4–0.6% of patients while
wearing WCD.8,9,13 The majority of these patients died. Sudden
cardiac death during WCD wearing may also occur after appropri-
ate and successful shock delivery (95–98% of all WCD shocks
successfully terminate VT/VF events with the first shock) due to
electromechanical dissociation, particularly in patients with severely
reduced ventricular function.
Conclusions
The WCD is a useful tool to bridge a temporarily increased risk for
SCD that safely terminates ventricular tachyarrhythmias with high
clinical success. Approximately 1–2% patients per month receive
an appropriate shock, with ,1% of inappropriate shocks due to
advanced detection criteria and the alert system that allows patients
to withheld therapy. National and international societies now rec-
ommend WCD use in different patient populations and clinical
scenarios.2,18–20,22,53,54 The main indication for WCD is as a bridge
to ICD implantation or until the arrhythmic risk subsides. A major
limitation is the lack of prospective, randomized trials for the dis-
cussed underlying diseases or debatable ICD indications. Therefore,
the guidelines are quite general and mainly based on expert opinion
(Table 2). A suggested algorithm to use the WCD to bridge a time
period of undetermined risk of SCD is depicted in Figure 5.
Current guidelines for ICD therapy are mostly based on trials that
started to enrol patients .10–15 years ago. Since then, insight
into the pathophysiology of arrhythmias, methods of risk stratifica-
tion, and therapeutic approaches have improved. Implantable
cardioverter-defibrillator therapy is not free from complications,
and we learned that with new therapies LV function may recover,
and with this, the risk of SCD will decrease. It is time to re-evaluate
the true arrhythmic risk for primary prevention of SCD in some of
the underlying cardiac morbidities with new randomized controlled
trials. The WCD will be the right tool to help performing these
trials. The clinical value of the WCD must be measured not only
by the number of terminated arrhythmic events, but also by success-
fully performed risk assessment and by the number of prevented
unnecessary ICD implantations.
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